Literature DB >> 26768963

The role of HIF in immunity and inflammation.

Eoin P Cummins1, Ciara E Keogh1, Daniel Crean1, Cormac T Taylor2.   

Abstract

Uncontrolled or non-resolving inflammation underpins a range of disease states including rheumatoid arthritis, inflammatory bowel disease and atherosclerosis. Hypoxia is a prominent feature of chronically inflamed tissues. This is due to elevated oxygen consumption by highly metabolically active inflamed resident cells and activated infiltrating immunocytes, as well as diminished oxygen supply due to vascular dysfunction. Tissue hypoxia can have a significant impact upon inflammatory signaling pathways in immune and non-immune cells and this can impact upon disease progression. In this review, we will discuss the relationship between tissue hypoxia and inflammation and identify how hypoxia-sensitive signaling pathways are potential therapeutic targets in chronic inflammatory disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hypoxia; hypoxia inducible factor; inflammation; leukocyte

Mesh:

Substances:

Year:  2016        PMID: 26768963     DOI: 10.1016/j.mam.2015.12.004

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  47 in total

Review 1.  Inside the hypoxic tumour: reprogramming of the DDR and radioresistance.

Authors:  Katheryn Begg; Mahvash Tavassoli
Journal:  Cell Death Discov       Date:  2020-08-18

2.  Regulatory sequence analysis of semaphorin 4D 5' non-coding region.

Authors:  Lijuan Qiu; Hongchao Jiang; Jia Luo; Juemin Xi; Xiaodan Wang; Yue Pan; Junying Chen; Yujiao Zhao; Qiangming Sun
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

3.  Hypoxic modulation of hepatocyte responses to the cytokine interleukin-22.

Authors:  Scott A Budda; Krishna Bhattarai; Justine L Alexander; Lauren A Zenewicz
Journal:  Immunol Cell Biol       Date:  2016-10-31       Impact factor: 5.126

4.  Nitric oxide mediates prolyl hydroxylase 3 expression in mesangial cells and in glomerulonephritis.

Authors:  Ahmed Aglan; Sebastian Longen; Nathalie Dehne; Yvette Köhler; Mohamed Hassan; Martina Beck; Claudia Tredup; Meike Boosen; Tzung-Harn Louise Hsieh; Liliana Schaefer; Karl-Friedrich Beck; Josef Pfeilschifter
Journal:  J Mol Med (Berl)       Date:  2017-01-04       Impact factor: 4.599

5.  Hypoxia-inducible factors: a central link between inflammation and cancer.

Authors:  Daniel Triner; Yatrik M Shah
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

Review 6.  Hypoxia-dependent regulation of inflammatory pathways in immune cells.

Authors:  Cormac T Taylor; Glen Doherty; Padraic G Fallon; Eoin P Cummins
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

Review 7.  Regulation of immunity and inflammation by hypoxia in immunological niches.

Authors:  Cormac T Taylor; Sean P Colgan
Journal:  Nat Rev Immunol       Date:  2017-10-03       Impact factor: 53.106

8.  Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions.

Authors:  Chelsey J F Smith; Kenneth L Jones; Diana L Johnson; Gretchen Bandoli; Loan K Robinson; Arthur Kavanaugh; Christina D Chambers
Journal:  Am J Med Genet A       Date:  2018-01-17       Impact factor: 2.802

9.  CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes.

Authors:  Sara Labiano; Florinda Meléndez-Rodríguez; Asís Palazón; Álvaro Teijeira; Saray Garasa; Iñaki Etxeberria; M Ángela Aznar; Alfonso R Sánchez-Paulete; Arantza Azpilikueta; Elixabet Bolaños; Carmen Molina; Hortensia de la Fuente; Patricia Maiso; Francisco Sánchez-Madrid; Manuel Ortiz de Landázuri; Julián Aragonés; Ignacio Melero
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

10.  Simulated aeromedical evacuation exacerbates burn induced lung injury: targeting mitochondrial DNA for reversal.

Authors:  Meng-Jing Xiao; Xiao-Fang Zou; Bin Li; Bao-Long Li; Shi-Jian Wu; Bo Zhang
Journal:  Mil Med Res       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.